Edgewise Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026The company sold its main drug program for $1.55 billion upfront plus up to $1.1 billion in future milestone payments.
Shareholders voted on leadership and confirmed KPMG as the company's accountant for 2026.
The company announced a major asset sale deal that could bring in up to $2.65 billion total if milestone goals are met.
The company released its earnings report for the first three months of 2026.
The company disclosed detailed financial statements and business updates for the first quarter.
The company released its yearly earnings report showing how the business performed in 2025.
The company announced its final quarter and complete-year 2025 earnings to shareholders.
Stocky reads Edgewise Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Edgewise Therapeutics, Inc.'s most recent tracked filing was a 8-K on 13 Jul 2026: Servier completes $1.55 billion sevasemten acquisition.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.